Breaking News Instant updates and real-time market news.

INCY

Incyte

$94.78

-0.91 (-0.95%)

, MRK

Merck

$62.66

-0.14 (-0.22%)

08:59
10/07/16
10/07
08:59
10/07/16
08:59

Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink

Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

INCY

Incyte

$94.78

-0.91 (-0.95%)

MRK

Merck

$62.66

-0.14 (-0.22%)

  • 07

    Oct

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

INCY Incyte
$94.78

-0.91 (-0.95%)

09/29/16
RAJA
09/29/16
UPGRADE
Target $115
RAJA
Outperform
Incyte upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
MRK Merck
$62.66

-0.14 (-0.22%)

08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.

TODAY'S FREE FLY STORIES

PLYA

Playa Hotels & Resorts

$11.31

0.03 (0.27%)

09:00
01/18/18
01/18
09:00
01/18/18
09:00
Syndicate
Playa Hotels & Resorts 6M share Block Trade priced at $10.80 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

RARX

RA Pharmaceuticals

09:00
01/18/18
01/18
09:00
01/18/18
09:00
Initiation
RA Pharmaceuticals initiated  »

RA Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
01/18/18
01/18
09:00
01/18/18
09:00
General news
The 41k initial claims drop to a 45-year low of 220k »

The 41k initial claims…

AGIO

Agios Pharmaceuticals

$70.33

1.53 (2.22%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 19

    Jan

PRTK

Paratek Pharmaceuticals

$17.68

-0.075 (-0.42%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Syndicate
Paratek Pharmaceuticals 3.11M share Spot Secondary priced at $16.10 »

BTIG acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ALXN

Alexion

$122.12

-2.36 (-1.90%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Initiation
Alexion initiated  »

Alexion assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTZ

MasTec

$51.90

0.75 (1.47%)

08:59
01/18/18
01/18
08:59
01/18/18
08:59
Recommendations
MasTec analyst commentary  »

MasTec price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$57.18

0.25 (0.44%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Downgrade
Continental Resources rating change  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GATX

GATX

$65.21

-0.5 (-0.76%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Earnings
GATX reports Q4 non-GAAP EPS 68c, consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

XLRN

Acceleron

$44.99

-0.03 (-0.07%)

08:57
01/18/18
01/18
08:57
01/18/18
08:57
Initiation
Acceleron initiated  »

Acceleron assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$231.37

2.83 (1.24%)

08:56
01/18/18
01/18
08:56
01/18/18
08:56
Hot Stocks
Becton Dickinson says enrollment complete in Lutonix below-the-knee trial »

BD announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

SCHW

Charles Schwab

$56.09

0.56 (1.01%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Recommendations
Charles Schwab analyst commentary  »

Charles Schwab price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.18

-0.06 (-0.19%)

, GE

General Electric

$17.35

-0.86 (-4.72%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Options
Notable open interest changes for January 18th »

Wednesday's total…

BAC

Bank of America

$31.18

-0.06 (-0.19%)

GE

General Electric

$17.35

-0.86 (-4.72%)

FB

Facebook

$177.60

-0.79 (-0.44%)

BABA

Alibaba

$183.83

1.43 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 07

    Feb

  • 15

    Feb

  • 28

    Feb

08:55
01/18/18
01/18
08:55
01/18/18
08:55
General news
U.S. housing starts dropped 8.2% to 1.192 M in December »

U.S. housing starts…

ABM

ABM

$38.73

0.26 (0.68%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Conference/Events
ABM to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

, AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

08:55
01/18/18
01/18
08:55
01/18/18
08:55
Conference/Events
Antero Resources to host analyst day »

Analyst Day to be held in…

AMGP

Antero Midstream GP

$20.89

-0.11 (-0.52%)

AM

Antero Midstream Partners

$30.95

-0.8 (-2.52%)

AR

Antero Resources

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

BIVV

Bioverativ

$62.32

-1.55 (-2.43%)

08:54
01/18/18
01/18
08:54
01/18/18
08:54
Initiation
Bioverativ initiated  »

Bioverativ assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 25

    Apr

UTHR

United Therapeutics

$140.32

5.2 (3.85%)

08:54
01/18/18
01/18
08:54
01/18/18
08:54
Initiation
United Therapeutics initiated  »

United Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$82.47

2.05 (2.55%)

08:53
01/18/18
01/18
08:53
01/18/18
08:53
Recommendations
PayPal analyst commentary  »

PayPal Q4 may see upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

EDGE

Edge Therapeutics

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Initiation
Edge Therapeutics initiated  »

Edge Therapeutics assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$90.14

1.79 (2.03%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Recommendations
Microsoft analyst commentary  »

Microsoft price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 31

    Jan

  • 07

    Feb

SNAP

Snap

$13.52

0.02 (0.15%)

, FB

Facebook

$177.60

-0.79 (-0.44%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Conference/Events
SunTrust Internet & digital media analyst holds analyst/industry conference call »

Internet & Digital…

SNAP

Snap

$13.52

0.02 (0.15%)

FB

Facebook

$177.60

-0.79 (-0.44%)

GOOG

Alphabet

$1,131.98

10.22 (0.91%)

GOOGL

Alphabet Class A

$1,139.10

8.4 (0.74%)

TWTR

Twitter

$24.56

-0.1 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

  • 18

    Mar

BMRN

BioMarin

$89.64

-0.6 (-0.66%)

08:52
01/18/18
01/18
08:52
01/18/18
08:52
Initiation
BioMarin initiated  »

BioMarin assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 25

    May

LEN

Lennar

$70.71

1.93 (2.81%)

08:51
01/18/18
01/18
08:51
01/18/18
08:51
Upgrade
Lennar rating change  »

Lennar upgraded to Buy at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICBK

County Bancorp

$30.73

-1.57 (-4.86%)

08:51
01/18/18
01/18
08:51
01/18/18
08:51
Earnings
County Bancorp reports Q4 EPS 30c, consensus 47c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.